Dexcom Q2 revenue $871.3M (+25% YoY), raises FY 2023 guidance

DEXCOM INC

2023-Q2 EPS reported $0.40 revenue$1,612,800,000

Revenue $871.3M (+25% YoY); GAAP EPS $0.28, non-GAAP EPS $0.34.
Raised FY 2023 revenue guidance to $3.50-3.55B (20-22% growth); Non-GAAP op margin ~17%.
International revenue +38% reported (+40% organic); U.S. +21%.
GAAP op margin 14.7% (+360 bps YoY); Non-GAAP op margin 18.2% (+360 bps).
Initiated commercial production at Malaysia facility; completed $1.25B convertible notes offering.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DEXCOM INC reported the quarter ended June 30, 2023 results: revenue $871.3 million, net income $115.9 million, EPS $0.28 per diluted share. Guidance raised.

Period: the quarter ended June 30, 2023
Revenue: $871.3 million
Net income: $115.9 million
EPS: $0.28 per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

its financial results as of and for the quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights: • Revenue grew 25% versus the same quarter of the prior year to $871.3 million on a reported basis and 26% on an organic 1 basis. • U.S. revenue growth of 21% and international revenue growth of 38% on a reported basis. International revenue growth was 40%

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

DEXCOM INC filing history →

Source: SEC EDGAR

accession 0001093557-23-000173

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.